Eli Lilly and Company $LLY Shares Bought by Ergawealth Advisors Inc.

Ergawealth Advisors Inc. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 4.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 626 shares of the company’s stock after purchasing an additional 24 shares during the quarter. Ergawealth Advisors Inc.’s holdings in Eli Lilly and Company were worth $488,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. WestEnd Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department lifted its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company in the first quarter worth about $40,000. Finally, TD Capital Management LLC increased its position in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $840.46 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The business’s 50-day moving average price is $734.60 and its two-hundred day moving average price is $765.98. The company has a market capitalization of $795.47 billion, a P/E ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the company earned $3.92 EPS. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LLY shares. Morgan Stanley reduced their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday. Cantor Fitzgerald decreased their target price on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Leerink Partners reissued a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $938.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.